Beta Bionics
Irvine
About Beta Bionics
Beta Bionics is a biotechnology company that develops an integrated bionic pancreas system called the iLet. The iLet Bionic Pancreas System was granted breakthrough designation in all configurations (insulin-only, glucagon-only, and bihormonal), including use with Zealand Pharma’s dasiglucagon, a glucagon analogue with a stability profile in a ready-to-use aqueous solution. It also offers a bionic pancreas device for glucose metabolism to the diabetes community.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 251 – 500
- Estimated revenue: $10K – $50K
- Total funding: $353.5M
- Funding stage: IPO
- Last round: Series E (Nov 2024)
- Ticker: nasdaq:BBNX
- Website: betabionics.com
- Phone: 909-800-3351
Industries & Categories
Biotechnology, Diabetes, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/beta-bionics-11953 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.